1. Scrip
  2. >>Podcasts
  3. >>Scrip's Five Must-Know Things

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: 2025’S biggest launches; 2024 deal metrics declined; GSK’s meningococcal vaccine; Arcus’s kidney cancer results; and Novartis on its India hub.

Scrip Five Must Know Things
weekly audio roundup of selected content from Scrip's global team

Join us for an audio catch-up on the major events in the global biopharma industry over the past business week, as reported by Scrip‘s global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 21 February 2025, including: 2025’S biggest launches; 2024 deal metrics declined; GSK’s meningococcal vaccine; Arcus’s kidney cancer results; and Novartis on its India hub.

This and all our other podcasts are available on the Citeline channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

2025’s Biggest New Launches

Biopharma Deal Metrics Declined Across The Board In 2024

GSK To Maintain Lead With Newly Approved Meningococcal Vaccine Penmenvy

Arcus’s Casdatifan Differentiates, But Data Overshadowed By Gilead Opting Out

Novartis Development Head On The India Hub, AI And Not Doing ‘Me Too’ Stuff In Obesity

More from Scrip's Five Must-Know Things

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: Pfizer tops pharma leaderboard; AstraZeneca buys into in vivo cell therapy; Almirall looks to dominate derma spectrum; Incyte’s HS contender looks approvable; and MSD’s Williams says pharma should shorten tech adoption cycles.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: Roche’s big new obesity deal; J&J opts out of next-gen Darzalex; Arvinas and Pfizer’s protein degrader misses Phase III endpoint; Kelun wins first TROP2 ADC approval in lung cancer; and big name brands poised to lose US exclusivity.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: low-cost Wegovy an alternative for US self-payers; Bayer rolls up sleeves for turnaround; taking the pulse of NewCo creation; the outlook for Alzheimer’s; and India’s rare disease landscape.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: which big companies face the least LOE hit?; IPOs rise in 2024; Pfizer cuts last AAV gene therapy program; balance and focus suggested for globalizing Chinese firms; and Scrip Asks on therapeutic area advances.

More from Scrip

Quotables: Pharma Leaders On The Month’s Hot Topics

 
• By Anabel Costa-Ferreira

The highlights of recent comments and insights from industry executives on the key issues covered in Scrip.

RemeGen Fast-Tracks Potential World-First BLys/APRIL Agent For gMG In Global Phase III Trial

 
• By Dexter Jie Yan

RemeGen is planning to complete enrolment in the global Phase III RemeMG study with telitacicept in generalized myasthenia gravis by the end of 2025 or early 2026. The Chinese firm has already sidelined two other global Phase III trials with the molecule to prioritize the indication.

Finance Watch: European And Japanese Biotechs See VC Investor Interest In March

 
• By Mandy Jackson

Private Company Edition: The latest group of drug developers to announce venture capital financings is remarkable for its geographic diversity, from Character Biosciences’ $93m series B round in the US to Augustine’s $85m series B in Belgium to a $29.2m series C for Aculys in Japan.